Real World Outcomes Using Novel Agents for AML in the UK
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
CC-486 and Venetoclax for Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
- Status
- TERMINATED
- Phase
- PHASE1
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
- Status
- UNKNOWN
- Phase
- NA
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- Status
- WITHDRAWN
- Phase
- PHASE2
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Status
- RECRUITING
- Phase
- PHASE3
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE3
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Status
- RECRUITING
- Phase
- PHASE2